Corcept Therapeutics/$CORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Ticker
$CORT
Sector
Primary listing
Employees
730
Headquarters
Website
CORT Metrics
BasicAdvanced
$4.4B
50.84
$0.82
0.31
-
Price and volume
Market cap
$4.4B
Beta
0.31
52-week high
$91.00
52-week low
$28.66
Average daily volume
1.9M
Financial strength
Current ratio
2.923
Quick ratio
2.601
Long term debt to equity
0.775
Total debt to equity
0.943
Profitability
EBITDA (TTM)
45.946
Gross margin (TTM)
98.30%
Net profit margin (TTM)
13.09%
Operating margin (TTM)
5.88%
Effective tax rate (TTM)
-49.94%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
3.34%
Return on equity (TTM)
15.01%
Valuation
Price to earnings (TTM)
50.841
Price to revenue (TTM)
5.687
Price to book
6.82
Price to tangible book (TTM)
6.82
Price to free cash flow (TTM)
30.539
Free cash flow yield (TTM)
3.27%
Free cash flow per share (TTM)
1.365
Growth
Revenue change (TTM)
12.79%
Earnings per share change (TTM)
-33.33%
3-year revenue growth (CAGR)
23.74%
10-year revenue growth (CAGR)
31.23%
3-year earnings per share growth (CAGR)
-1.95%
10-year earnings per share growth (CAGR)
29.89%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
CORT News
AllArticlesVideos
CORT DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action - CORT
Newsfile Corp·5 hours ago
ROSEN, A TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action - CORT
Newsfile Corp·1 day ago
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corcept Therapeutics stock?
Corcept Therapeutics (CORT) has a market cap of $4.4B as of April 08, 2026.
What is the P/E ratio for Corcept Therapeutics stock?
The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 50.84 as of April 08, 2026.
Does Corcept Therapeutics stock pay dividends?
No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of April 08, 2026.
When is the next Corcept Therapeutics dividend payment date?
Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Corcept Therapeutics?
Corcept Therapeutics (CORT) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.